Get startedLog in
    Picture of Structure Therapeutics logo

    GPCR — Structure Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapSucker Stock
    All News

    Brief: Structure Therapeutics - Aleniglipron Shows Up To 16.2% Weight Loss Beyond 36 Weeks In Phase 2B Trial

    Picture of Structure Therapeutics logoStructure Therapeutics
    05/06/2026 21:23
    BRIEF-Structure Therapeutics - Aleniglipron Shows Up To 16.2% Weight Loss Beyond 36 Weeks In Phase 2B Trial
    June 5 (Reuters) - Structure Therapeutics Inc GPCR.O:
    • STRUCTURE THERAPEUTICS - ALENIGLIPRON SHOWS UP TO 16.2% WEIGHT LOSS BEYOND 36 WEEKS IN PHASE 2B TRIAL
    • STRUCTURE THERAPEUTICS - PHASE 3 PROGRAM FOR ALENIGLIPRON TO INITIATE IN Q3 2026
    • STRUCTURE THERAPEUTICS - ALENIGLIPRON DEMONSTRATES 10.4% DISCONTINUATION RATE WITH FAVORABLE TOLERABILITY
    Source text: ID:nGNXwbK7L
    Further company coverage: GPCR.O

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Structure Therapeutics

    See all news